Search

Your search keyword '"Lin, Gui‐Nan"' showing total 18 results
Start Over Author "Lin, Gui‐Nan"
18 results on '"Lin, Gui‐Nan"'

5. Pathologic complete response after neoadjuvant tislelizumab and chemotherapy for Pancoast tumor: A case report

Author

Tang, Wen‐Fang, primary, Xu, Wei, additional, Huang, Wei‐Zhao, additional, Lin, Gui‐Nan, additional, Zeng, Yu‐Mei, additional, Lin, Jie‐Shan, additional, Wu, Min, additional, Bao, Hua, additional, Peng, Jie‐Wen, additional, Jiang, Hai‐Ming, additional, Wang, Heng‐Qiang, additional, Wu, Ying‐Meng, additional, Ye, Hong‐Yu, additional, and Liang, Yi, additional

Published
2021
Full Text
View/download PDF

10. Chemotherapy Near the End of Life for Chinese Patients with Solid Malignancies

Author

Sheng, Jin, primary, Zhang, Ya-Xiong, additional, He, Xiao-Bo, additional, Fang, Wen-Feng, additional, Yang, Yun-Peng, additional, Lin, Gui-Nan, additional, Wu, Xuan, additional, Li, Ning, additional, Zhang, Jing, additional, Zhai, Lin-Zhu, additional, Zhao, Yuan-Yuan, additional, Huang, Yan, additional, Zhou, Ning-Ning, additional, Zhao, Hong-Yun, additional, and Zhang, Li, additional

Published
2017
Full Text
View/download PDF

13. Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line

Author

Lu Yue, Li Jie, Wang Guo-Bao, Geng Qi-rong, Chen Xiao-qin, and Lin Gui-Nan

Subjects
Cancer Research, Stromal cell, Cell Survival, Blotting, Western, Down-Regulation, Antineoplastic Agents, Apoptosis, Bone Marrow Cells, Biology, Pharmacology, Arsenicals, Myelogenous, Inhibitory Concentration 50, Arsenic Trioxide, hemic and lymphatic diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, medicine, Cell Adhesion, Cytotoxic T cell, Humans, Cells, Cultured, Dose-Response Relationship, Drug, Integrin beta1, Daunorubicin, Cytarabine, Drug Synergism, Oxides, Hematology, medicine.disease, Minimal residual disease, Coculture Techniques, Leukemia, medicine.anatomical_structure, Oncology, Drug Resistance, Neoplasm, Cancer research, Bone marrow, Stromal Cells, K562 Cells, Chronic myelogenous leukemia, K562 cells
Abstract

The bone marrow microenvironment protects leukemia cells from drug-induced damage, and cell adhesion-mediated drug resistance (CAM-DR) is the main obstacle for the eradication of bone marrow minimal residual disease. In this study, we evaluated the survival response of K562 cells co-cultured with bone marrow stromal cells (BMSCs) derived from patients with chronic myelogenous leukemia (CML). Co-cultured K562 cells had a survival advantage after exposure to cytotoxic drugs compared to suspended K562 cells, but there was no survival difference between the two groups following exposure to As(2)O(3). The cytotoxicity of As(2)O(3) combined with cytotoxic drugs had an additive effect in the suspension group and a synergistic effect in the co-cultured group. Similar apoptotic responses were found using flow cytometry assays. As(2)O(3) treatment caused a dose dependent reduction of the adhesion ability of K562 cells to BMSCs, and Western blot analysis revealed that the treatment of K562 cells with As(2)O(3) led to down-regulation of beta(1)-integrin.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results